Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Caldwell, R.D., Qiu, H., Askew, B.C., Bender, A.T., Brugger, N., Camps, M., Dhanabal, M., Dutt, V., Eichhorn, T., Gardberg, A.S., Goutopoulos, A., Grenningloh, R., Head, J., Healey, B., Hodous, B.L., Huck, B.R., Johnson, T.L., Jones, C., Jones, R.C., Mochalkin, I., Morandi, F., Nguyen, N., Meyring, M., Potnick, J.R., Santos, D.C., Schmidt, R., Sherer, B., Shutes, A., Urbahns, K., Follis, A.V., Wegener, A.A., Zimmerli, S.C., Liu-Bujalski, L.
J.Med.Chem.
